Short answer
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $402M (up 5.6% year over year) with net income of −$5M.
Q3 2025 key financials · XBRL
- Revenue
- $402M
- +5.6% YoY · −3.3% QoQ
- Net income
- −$5M
- +49.5% YoY · +98.9% QoQ
- Operating margin
- 2.9%
- EPS (diluted)
- −$0.07
- +50.0% YoY · +98.9% QoQ
Source: XBRL data from the INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Q3 2025 10-Q on SEC EDGAR. USD.
INTEGRA LIFESCIENCES HOLDINGS CORP Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Near-term outlook: Braintree facility operationalization and SurgiMend transition expected in 2026
- DuraSorb PMA approval targeted for 2026
- Headwinds: FDA warning letters, quality-system remediation and potential regulatory delays
- Emerging risks: tariffs, supply-chain disruptions, macroeconomic uncertainty and FDA workforce reductions
Risk Factors
- No material changes to 10-K and March 31, 2025 10-Q risk factors
- No newly added risk factor or triggering event disclosed
- No updated regulatory, legal, or compliance risk identified
- Carried-forward operational, competitive, market, and financial risks unchanged from prior filings
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other INTEGRA LIFESCIENCES HOLDINGS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.